Clinical Roundup Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows September 12, 2025Vol.51 No.33
Clinical Roundup Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows September 12, 2025Vol.51 No.33
Clinical Roundup Preclinical study reveals how HPV reprograms immune cells to help cancer grow September 12, 2025Vol.51 No.33
Clinical Roundup Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy September 12, 2025Vol.51 No.33
Clinical Roundup WashU Medicine genetic study suggests ways to catch blood cancer earlier September 12, 2025Vol.51 No.33
Drugs & Targets FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer September 12, 2025Vol.51 No.33
Drugs & Targets FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC September 12, 2025Vol.51 No.33
Drugs & Targets FDA seeks academic and patient advocate research partners for oncology data analysis September 12, 2025Vol.51 No.33
Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing September 05, 2025Vol.51 No.32By Jacquelyn Cobb
